Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

Publication | Closed Access

DOI

276

Citations

References

2007

Year

Rajesh Krishna, Matt S. Anderson, Arthur Bergman, Bo Jin, Marissa S. Fallon, Josée Côté, Kim Rosko, C.M. Chavez-Eng, Ryan Lutz, Daniel M. Bloomfield,

The Lancet

Metabolic SyndromeHypertensionHealthy IndividualsLipid DisorderCardiovascular DiseaseMedicineDiabetesHyperlipidemiaLipoprotein MetabolismPharmacologyAtherosclerosisDyslipidemiaPlacebo-controlled Phase